The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review

Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta(TM)) is a new generation multi-targeted antifola...

Descripción completa

Detalles Bibliográficos
Autores principales: Roche, Michael, Parisi, Laura, Li, Linda, Knehans, Amy, Phaeton, Rebecca, Kesterson, Joshua P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007165/
https://www.ncbi.nlm.nih.gov/pubmed/29983902
http://dx.doi.org/10.4081/oncol.2018.346
Descripción
Sumario:Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta(TM)) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current literature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.

Ejemplares similares